# Vertex Ventures HC (Vertex Ventures Healthcare)

> Vertex Ventures HC (VVHC) is a global healthcare venture capital firm investing in biotech and medtech companies developing transformative therapies and medical technologies. VVHC is part of the Vertex global network of venture capital funds, with affiliates in China, Israel, Japan, Southeast Asia and India, and the US.

Key facts:
- Over 25 portfolio companies; 3 FDA-cleared products; 30 clinical-stage assets; ~$500M under management.
- Investment focus: biotech (therapeutics, cell and gene therapy, oncology, immunology) and medtech (implantable devices, drug delivery, neuromodulation, ophthalmology).
- The firm supports its portfolio through key growth and value-creation milestones.
- Website: https://www.vertexventureshc.com
- Contact: hello@vertexventureshc.com — 250 North Bridge Road, #11-01, Raffles City Tower, Singapore 179101. Tel +65 6828 8088.

Site structure note: the site is a small marketing site. The portfolio and latest-news listings live as sections on the homepage (`/#portfolio`, `/#latestNews`); individual news articles live under `/news/`. Some news items link directly to third-party sources rather than to a page on this site.

## Main pages

- [Home](https://www.vertexventureshc.com/): Firm overview, statistics, featured portfolio companies, full investment list, and latest news.
- [News](https://www.vertexventureshc.com/news/): Paginated index of portfolio and firm news.
- [Contact](https://www.vertexventureshc.com/contact/): Singapore office address, phone, fax, and email.
- [Legal](https://www.vertexventureshc.com/legal/): Terms of Use, trademark and privacy notices, disclaimers. Governed by the laws of Singapore.

## Portfolio — biotech

- [Bicycle Therapeutics](https://www.bicycletherapeutics.com/) (NASDAQ: BCYC): First-in-class medicines using bicyclic peptides (Bicycles®) to treat cancer and other debilitating diseases.
- [Boundless Bio](https://boundlessbio.com/) (NASDAQ: BOLD): ecDNA-directed therapies (ecDTx) for aggressive gene-amplified cancers.
- [Elevate Bio](https://www.elevate.bio): Cell and gene therapy technology and manufacturing platform, including BaseCamp, a centralized R&D and manufacturing organization.
- [Elevation Oncology](https://elevationoncology.com/) (NASDAQ: ELEV): Differentiated antibody-drug conjugates, including Claudin 18.2 and HER3 programs.
- [Epirium Bio](http://epirium.com/): Therapeutics leveraging muscle biology, tissue regeneration, and mitochondrial function.
- [EyeBio](https://eyebiotech.com/): Antibody therapeutics to protect, restore, and improve vision. Acquired by Merck.
- [Indapta Therapeutics](https://indapta.com/): Off-the-shelf allogeneic FcRγ-deficient natural killer (G-NK) cell therapy for cancer.
- [Matchpoint Therapeutics](https://matchpointtx.com/): Precision covalent small-molecule medicines for immune diseases.
- [Neumora](https://neumoratx.com/) (NASDAQ: NMRA): Data-driven precision neuroscience platform for brain disease heterogeneity.
- [Obsidian Therapeutics](https://www.obsidiantx.com/): Controllable cell and gene therapy for cancer via the cytoDRIVE® platform.
- [Palleon Pharmaceuticals](https://palleonpharma.com/): Glycan-sensing checkpoint therapeutics for cancer and inflammatory diseases.
- [Redona Therapeutics](https://redonatx.com/): Small molecules targeting nucleic acid processing and sensing enzymes, including in cancer.
- [Septerna](https://septerna.com/) (NASDAQ: SEPN): Oral therapeutics targeting difficult-to-drug GPCRs via the GPCR Native Complex™ platform.
- [Sonoma Biotherapeutics](https://www.sonomabio.com/): Regulatory T cell (Treg) living cell therapies to restore immune balance.
- [Sonothera](https://sonothera.com/): Non-viral gene therapy using ultrasound and microbubbles for redosable tissue transduction.
- [TORL Biotherapeutics](https://torlbio.com/): Clinical-stage antibody-drug conjugates for ovarian cancer, NSCLC, and other tumors.
- [Visterra](https://www.visterrainc.com/): HIEROTOPE epitope-identification technology for antibody design. Acquired by Otsuka.

## Portfolio — medtech

- [Allay Therapeutics](https://www.allaytx.com/): Clinical-stage polymer-drug formulation for extended post-operative pain control (ATX101).
- [Earlens Corporation](https://www.earlens.com/): Hearing aid that uses light to drive eardrum vibration directly.
- [Ivantis](https://www.ivantisinc.com/): Hydrus Microstent, an FDA-approved minimally invasive glaucoma stent (MIGS). Acquired by Alcon.
- [Moximed](https://www.moximed.com/): MISHA Knee System, an implantable shock absorber for knee osteoarthritis.
- [Neuspera](http://neuspera.com/): Battery-free implantable sacral neuromodulation system for urgency urinary incontinence.
- [Nuvaira](https://www.nuvaira.com/): Minimally invasive Targeted Lung Denervation (TLD) therapy for COPD and asthma.
- [Olympic Ophthalmics](https://olympicophthalmics.com/): Non-invasive device for the treatment of dry eye.
- [Spyglass Pharma](https://www.spyglasspharma.com/): Controlled-release intraocular drug delivery for glaucoma patients undergoing cataract surgery.
- Twelve: Transcatheter mitral valve replacement (TMVR), spun out of the Foundry. Acquired by Medtronic in 2015.

## News

- [Nobel Laureate-founded Bicycle Therapeutics Set to Produce Cancer Treatments out of Uranium](https://www.vertexventureshc.com/news/bicycle-therapeutics-establishes-multiple-strategic-partnerships-to-create-end-to-end-supply-chain-to-support-its-wholly-owned-radiopharmaceutical-pipeline/) (2025-12-16)
- [Sonoma Biotherapeutics' Fred Ramsdell Receives 2025 Nobel Prize in Physiology or Medicine](https://www.vertexventureshc.com/news/6fd914c0-1180-4553-b819-a01b86fd3c28/) (2025-10-06)
- [Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101](https://www.vertexventureshc.com/news/allay-therapeutics-announces-57-5m-series-d-financing-and-venture-debt-line-to-advance-atx101-and-its-ultra-sustained-pain-platform-for-post-surgical-pain-management/) (2025-06-05)
- [SpyGlass Pharma Raises $75 Million Series D Funding](https://www.vertexventureshc.com/news/spyglass-pharma-raises-75-million-series-d-funding-to-advance-its-long-term-drug-delivery-platform-for-glaucoma-patients/) (2025-06-02)
- [Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Advanced Melanoma at ASCO 2025](https://www.vertexventureshc.com/news/obsidian-therapeutics-announces-positive-clinical-data-from-obx-115-in-patients-with-advanced-melanoma-in-ongoing-multicenter-study-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting/) (2025-06-02)
- [First Patients Treated in a New Randomized Controlled Trial Evaluating the MISHA® Knee System](https://www.vertexventureshc.com/news/first-patients-treated-in-a-new-randomized-controlled-trial-evaluating-the-misha-knee-system-vs-non-surgical-treatment-for-knee-osteoarthritis/) (2025-05-29)
- [SpyGlass Pharma Presents 18-Month Visual Acuity Data for Its IOL-mounted Drug Delivery Platform](https://www.vertexventureshc.com/news/spyglass-pharma-presents-18-month-data-demonstrating-compelling-visual-acuity-results-with-their-iol-mounted-innovative-drug-delivery-platform/) (2025-04-24)
- [Neuspera Medical Announces Six-Month Clinical Trial Results for Battery-Free pSNM System](https://www.vertexventureshc.com/news/neuspera-medical-announces-landmark-six-month-clinical-trial-results-for-the-first-battery-free-percutaneous-sacral-neuromodulation-psnm-system-for-urgency-urinary-incontinence-management/) (2025-02-27)
- [ElevateBio Announces Preclinical Data for LETI-101 in Huntington's Disease](https://www.vertexventureshc.com/news/elevatebio-announces-compelling-preclinical-data-demonstrating-the-potential-of-leti-101-as-a-treatment-for-huntington-s-disease/) (2025-02-24)
- [Allay Therapeutics Announces FDA IND Acceptance for Pivotal Phase 2B Trial of ATX101](https://www.vertexventureshc.com/news/allay-therapeutics-announces-first-patients-dosed-in-pivotal-phase-2b-registration-trial-of-atx101-for-post-surgical-pain-management-after-knee-replacement-surgery/) (2025-02-18)
- [Vertex Ventures HC Announces Christine Brennan, Ph.D., Appointed to BIO Board of Directors](https://www.vertexventureshc.com/news/vertex-ventures-hc-announces-christine-brennan-ph-d-appointed-to-bio-board-of-directors/) (2024-12-03)
- [Vertex Ventures HC Announces $200 Million Fund III to Drive Innovation in Healthcare](https://www.vertexventureshc.com/news/vertex-ventures-hc-announces-200-million-fund-iii-to-drive-innovation-in-healthcare/) (2023-06-27)
- [SonoThera™ Expands Leadership Team Appointing Carolyne Zimmermann as Chief Business Officer](https://www.vertexventureshc.com/news/sonotheratm-expands-leadership-team-appointing-carolyne-zimmermann-as-chief-business-officer/) (2023-06-27)
- [The Power of Diversity & The Future of Funding](https://www.vertexventureshc.com/news/the-power-of-diversity-the-future-of-funding/) (2023-04-14)
- [SonoThera™ Receives Exclusive Licensing of GE HealthCare's Optison® and Sonazoid® Microbubble Products](https://www.vertexventureshc.com/news/sonotheratm-receives-exclusive-licensing-of-ge-healthcare-s-optison-and-sonazoid-microbubble-products-for-use-with-its-ultrasound-guided-gene-therapy-platform/) (2023-02-27)
- [Palleon Co-Founder Dr. Carolyn Bertozzi wins a Nobel Prize in Chemistry](https://www.vertexventureshc.com/news/palleon-co-founder-dr-carolyn-bertozzi-awarded-nobel-prize-in-chemistry-for-pioneering-methods-of-studying-glycobiology/) (2023-01-05)
- [Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making](https://www.vertexventureshc.com/news/legacies-60-biopharma-pioneers-over-60-who-helped-birth-a-tech-revolution-in-the-making/) (2021-05-19)
- [Taking biopharmaceutical Visterra from investment to multi-million dollar M&A](https://www.vertexventureshc.com/news/taking-biopharmaceutical-visterra-from-investment-to-multi-million-dollar-m-a/) (2018-07-26)
- [Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial](https://www.vertexventureshc.com/news/ivantis-announces-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/) (2018-04-16)
- [Palleon co-founder Dr. Carolyn Bertozzi describes how sugars interact with the immune system at TEDxStanford](https://www.vertexventureshc.com/news/palleon-scientific-co-founder-dr-carolyn-bertozzi-describes-how-sugars-interact-with-the-immune-system-at-tedxstanford/) (2018-01-08)
- [Ivantis Hits 2 Major Milestones for its Minimally Invasive Glaucoma Surgery (MIGS)](https://www.vertexventureshc.com/news/ivantis-hits-2-major-milestones-for-its-minimally-invasive-glaucoma-surgery/) (2018-01-08)

## Vertex global network

- [Vertex Ventures US](https://www.vvus.com)
- [Vertex Ventures China](https://vertexventures.cn/)
- [Vertex Ventures Israel](https://www.vertexventures.co.il/)
- [Vertex Ventures Japan](https://vertexventures.jp/en)
- [Vertex Ventures SEA & India](https://www.vertexventures.sg/)
- [Vertex Growth](https://vertexgrowth.com/)

## Optional

- [Sitemap](https://www.vertexventureshc.com/sitemap-index.xml): Machine-readable index of all published pages.
- [LinkedIn](https://www.linkedin.com/company/vertex-ventures-hc/): Firm updates and announcements.